Name | Number of supported studies | Average coverage | |
---|---|---|---|
CD8-positive, alpha-beta T cell | 22 studies | 30% ± 12% | |
gamma-delta T cell | 11 studies | 24% ± 5% | |
CD8-positive, alpha-beta memory T cell | 10 studies | 24% ± 6% | |
mucosal invariant T cell | 8 studies | 21% ± 4% | |
T cell | 6 studies | 22% ± 6% | |
mature NK T cell | 6 studies | 21% ± 4% | |
regulatory T cell | 6 studies | 27% ± 12% | |
exhausted T cell | 5 studies | 54% ± 11% | |
effector CD8-positive, alpha-beta T cell | 5 studies | 40% ± 17% | |
effector memory CD8-positive, alpha-beta T cell | 5 studies | 28% ± 13% | |
natural killer cell | 3 studies | 24% ± 5% | |
naive thymus-derived CD8-positive, alpha-beta T cell | 3 studies | 27% ± 3% | |
CD4-positive, alpha-beta cytotoxic T cell | 3 studies | 28% ± 11% |
Insufficient scRNA-seq data for expression of LAG3 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
uterus | 100% | 871.36 | 170 / 170 | 89% | 13.97 | 409 / 459 |
lung | 99% | 344.48 | 575 / 578 | 88% | 9.42 | 1022 / 1155 |
ovary | 100% | 1816.63 | 180 / 180 | 86% | 7.88 | 369 / 430 |
prostate | 100% | 351.22 | 244 / 245 | 75% | 3.54 | 377 / 502 |
intestine | 100% | 467.90 | 963 / 966 | 69% | 5.43 | 362 / 527 |
esophagus | 90% | 221.25 | 1301 / 1445 | 77% | 7.20 | 140 / 183 |
stomach | 89% | 174.84 | 320 / 359 | 71% | 7.10 | 203 / 286 |
breast | 88% | 124.42 | 404 / 459 | 68% | 6.76 | 763 / 1118 |
bladder | 90% | 178.14 | 19 / 21 | 65% | 8.01 | 326 / 504 |
liver | 97% | 251.35 | 220 / 226 | 45% | 4.24 | 183 / 406 |
skin | 49% | 44.16 | 893 / 1809 | 78% | 24.57 | 367 / 472 |
kidney | 69% | 93.39 | 61 / 89 | 55% | 7.65 | 493 / 901 |
thymus | 72% | 116.01 | 470 / 653 | 49% | 4.20 | 295 / 605 |
lymph node | 0% | 0 | 0 / 0 | 100% | 124.72 | 29 / 29 |
spleen | 100% | 1709.49 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 20.14 | 40 / 45 |
peripheral blood | 85% | 836.25 | 789 / 929 | 0% | 0 | 0 / 0 |
adipose | 83% | 150.05 | 997 / 1204 | 0% | 0 | 0 / 0 |
pancreas | 7% | 5.37 | 22 / 328 | 61% | 3.97 | 109 / 178 |
adrenal gland | 30% | 25.48 | 78 / 258 | 34% | 2.98 | 79 / 230 |
blood vessel | 50% | 54.81 | 672 / 1335 | 0% | 0 | 0 / 0 |
brain | 24% | 27.78 | 637 / 2642 | 26% | 1.41 | 184 / 705 |
heart | 48% | 65.46 | 413 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 35% | 6.88 | 28 / 80 |
muscle | 4% | 2.90 | 30 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0045590 | Biological process | negative regulation of regulatory T cell differentiation |
GO_0032703 | Biological process | negative regulation of interleukin-2 production |
GO_0042110 | Biological process | T cell activation |
GO_0050776 | Biological process | regulation of immune response |
GO_0045954 | Biological process | positive regulation of natural killer cell mediated cytotoxicity |
GO_0002270 | Biological process | plasmacytoid dendritic cell activation |
GO_0007166 | Biological process | cell surface receptor signaling pathway |
GO_0042267 | Biological process | natural killer cell mediated cytotoxicity |
GO_0009897 | Cellular component | external side of plasma membrane |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0004888 | Molecular function | transmembrane signaling receptor activity |
GO_0003823 | Molecular function | antigen binding |
GO_0042289 | Molecular function | MHC class II protein binding |
GO_0005515 | Molecular function | protein binding |
Gene name | LAG3 |
Protein name | Lymphocyte activation gene 3 protein (LAG-3) (CD antigen CD223) [Cleaved into: Secreted lymphocyte activation gene 3 protein (sLAG-3)] |
Synonyms | FDC |
Description | FUNCTION: Lymphocyte activation gene 3 protein: Inhibitory receptor on antigen activated T-cells . Delivers inhibitory signals upon binding to ligands, such as FGL1 (By similarity). FGL1 constitutes a major ligand of LAG3 and is responsible for LAG3 T-cell inhibitory function (By similarity). Following TCR engagement, LAG3 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity). May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1, possibly by acting as a coreceptor for PDCD1/PD-1 (By similarity). Negatively regulates the proliferation, activation, effector function and homeostasis of both CD8(+) and CD4(+) T-cells . Also mediates immune tolerance: constitutively expressed on a subset of regulatory T-cells (Tregs) and contributes to their suppressive function (By similarity). Also acts as a negative regulator of plasmacytoid dendritic cell (pDCs) activation (By similarity). Binds MHC class II (MHC-II); the precise role of MHC-II-binding is however unclear . .; FUNCTION: [Secreted lymphocyte activation gene 3 protein]: May function as a ligand for MHC class II (MHC-II) on antigen-presenting cells (APC), promoting APC activation/maturation and driving Th1 immune response. . |
Accessions | ENST00000203629.3 [P18627-1] ENST00000441671.6 [P18627-2] P18627 |